Guardant Health Lifts 2026 Revenue Outlook as Screening Surges

Guardant Health (GH ) announced on November 5, 2026 that it raised its full-year revenue outlook to $1.36 billion to $1.37 billion after third-quarter revenue increased 36% to $361.0 million, led by growth in Oncology and its Shield cancer-screening business.

The new range represents 38% to 40% growth over full-year 2025, compared with previous guidance of $1.34 billion to $1.36 billion and 36% to 38% growth. Guardant expects Screening revenue of $233 million to $238 million, up from $218 million to $230 million, on 285,000 to 290,000 Shield tests rather than 270,000 to 285,000. The annual outlook also calls for approximately 30% Oncology revenue growth, more than 50% Oncology volume growth and low-double-digit Biopharma & Data revenue growth.

Shield Volume More Than Triples

Oncology remained the largest quarterly revenue category at $231.3 million, up 25%, as test volume rose 58% to 117,000. Screening revenue jumped 180% to $67.6 million as Shield volume increased 246% to 83,000 tests from 24,000. Biopharma & Data revenue grew 8% to $59.0 million.

Commercial coverage for Shield now reaches more than 80% of eligible lives, with additions including UnitedHealth Group, Carelon Healthcare Services and EviCore. Co-CEO AmirAli Talasaz said recent policy updates extended coverage to approximately 100 million lives, and that the fully implemented, FDA-approved workflow’s lower cost of goods sold and higher throughput provide an operational foundation for future demand.

Higher Spending Widens the GAAP Loss

Gross profit rose 38% to $236.2 million, but GAAP gross margin held at 65%. Operating expenses climbed to $368.9 million from $270.6 million, primarily reflecting commercial infrastructure expansion, marketing supporting Screening and Oncology, and higher stock-based compensation. The spending increase outstripped the additional gross profit, helping widen the GAAP net loss to $124.4 million, or $0.93 per share, from $92.7 million, or $0.74.

The adjusted results moved in the other direction. Non-GAAP net loss, which excludes items such as stock-based compensation and related employer payroll taxes and intangible-asset amortization, narrowed to $38.8 million from $48.3 million. Free cash flow, defined by Guardant as net cash used in operating activities less purchases of property and equipment, was negative $37.2 million, compared with negative $45.8 million. Cash, cash equivalents and restricted cash totaled $1.1 billion as of September 30, 2026.

For the full year, Guardant now targets a 65% non-GAAP gross margin, narrowing its prior 64% to 65% range, but raised its non-GAAP operating-expense forecast to $1.105 billion to $1.125 billion from $1.080 billion to $1.100 billion. Expected free-cash-flow burn increased to $205 million to $220 million from $195 million to $205 million.

The revised outlook makes the expansion’s trade-off clear: faster test and revenue growth are accompanying smaller adjusted losses and better quarterly cash flow, while the wider GAAP loss and higher annual spending and cash-burn forecasts show the cost of expanding Screening and Oncology. Whether margin improvement and cash generation keep pace with that expansion is the central question left by the revised guidance.